A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B
Latest Information Update: 01 Dec 2025
At a glance
- Drugs CRMA 1001 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
Most Recent Events
- 07 Nov 2025 According to a Chroma Medicine media release, The company has initiated submission of Clinical Trial Applications (CTAs) for CRMA-1001. Pending regulatory clearance, the company anticipates initiating a Phase 1 first-in-human study in early 2026.
- 30 Sep 2025 Status changed from planning to not yet recruiting.
- 16 Dec 2024 New trial record